Nautilus Biotechnolgy
NAUT
77 hedge funds and large institutions have $150M invested in Nautilus Biotechnolgy in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 4 closing their positions.
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
5% more funds holding
Funds holding: 73 → 77 (+4)
0.54% more ownership
Funds ownership: 50.55% → 51.09% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
19% less capital invested
Capital invested by funds: $186M → $150M (-$36.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
+$1.6M |
| 2 |
BlackRock
New York
|
+$250K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$248K |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$129K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$355K |
| 2 |
Morgan Stanley
New York
|
-$222K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$82.1K |
| 4 |
AIG
American International Group
New York
|
-$73.1K |
| 5 |
JP Morgan Chase
New York
|
-$68.9K |
NAUT Hedge Fund Activity: Q2 2024 in Review
77 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q2 2024, worth a combined $150M — down 19% from $186M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NAUT positions and 4 closed out — a net gain of 4 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was ArchPoint Investors, opening a new position worth an estimated $1.6M. The largest seller was Vanguard Group, cutting an estimated $355K.
- 77 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q2 2024, up from 73 in Q1 2024.
- Funds reported $150M of Nautilus Biotechnolgy stock for Q2 2024, down 19% quarter-over-quarter.
- 8 funds opened new Nautilus Biotechnolgy positions in Q2 2024 and 4 closed out, a net change of +4 holders.
- The largest Nautilus Biotechnolgy buyer in Q2 2024 was ArchPoint Investors, an estimated $1.6M added.
- The largest Nautilus Biotechnolgy seller in Q2 2024 was Vanguard Group, an estimated $355K sold.
Based on aggregated 13F filings for Q2 2024.